## Table of Contents

### Perspectives

259  
**NOTCH Mutations: Multiple Faces in Human Malignancies**  
Li Mao  
*See related article, p. 277*

262  
**A Novel Target for Oral Cancer Chemoprevention? Notch Quite, Yet...**  
William N. William Jr and Adel K. El-Naggar  
*See related article, p. 277*

### Cancer ImmunoPrevention Series

266  
**The Antigenic Repertoire of Premalignant and High-Risk Lesions**  
Juan Pablo Marquez, Sasha E. Stanton, and Mary L. Disis

### Review

271  
**Gonadal Tumor in Frasier Syndrome: A Review and Classification**  
Jiro Ezaki, Kazunori Hashimoto, Tatsuo Asano, Shoichiro Kanda, Yuko Akioka, Motoshi Hattori, Tomoko Yamamoto, and Noriyuki Shibata

### Research Articles

277  
**Notch1 Mutations Are Drivers of Oral Tumorigenesis**  
Evgeny Izumchenko, Kai Sun, Sian Jones, Mariana Braith, Nishant Agrawal, Wayne Koch, Christine L. McCord, David R. Riley, Samuel V. Angiulo, Victor E. Velculescu, Wei-Wen Jiang, and David Sidransky  
*See related perspectives, p. 259 and p. 262*

287  
**Cleaved NOTCH1 Expression Pattern in Head and Neck Squamous Cell Carcinoma Is Associated with NOTCH1 Mutation, HPV Status, and High-Risk Features**  
Eleni M. Rettig, Christine H. Chung, Justin A. Bishop, Jason D. Howard, Rajni Sharma, Ryan J. Li, Christopher Douville, Rachel Karchin, Evgeny Izumchenko, David Sidransky, Wayne Koch, Joseph Califano, Nishant Agrawal, and Carole Fakhry

296  
**Prevention of Chemically Induced Urinary Bladder Cancers by Naproxen: Protocols to Reduce Gastric Toxicity in Humans Do Not Alter Preventive Efficacy**  
Ronald A. Lubet, James M. Scheiman, Ann Bode, Jonathan White, Lori Minasian, M. Margaret Juliana, Daniel L. Boring, Vernon E. Steele, and Clinton J. Grubbs

303  
**Id1 Deficiency Protects against Tumor Formation in ApcMin/+ Mice but Not in a Mouse Model of Colitis-Associated Colon Cancer**  
Ning Zhang, Kousha Subbaramaiah, Rhonda K. Yantiss, Xi Kathy Zhou, Yvette Chin, Robert Benezra, and Andrew J. Dannenberg

312  
**Smoking Is Associated with Acute and Chronic Prostatic Inflammation: Results from the REDUCE Study**  

318  
**Enhanced Antitumor Activity of 3-Bromopyruvate in Combination with Rapamycin In Vitro and In Vivo**  
Qi Zhang, Jing Pan, Ronald A. Lubet, Steven M. Komas, Balaraman Kalyanaraman, Yian Wang, and Ming You

327  
**Improved Innate Immune Responses by Frondanol A5, a Sea Cucumber Extract, Prevent Intestinal Tumorigenesis**  
Naveena B. Janakiram, Alfa Mohmed, Taylor Bryant, Stan Lightfoot, Peter D. Collin, Vernon E. Steele, and Chinhalapally V. Rao

### Letter to the Editor

338  
**Targeting Apoptosis Pathways in Cancer—Letter**  
Stephen Safe
Colorectal cancer (CRC) is the second leading cause of deaths among all cancers. The colonic tumor microenvironment is strongly associated with chronic inflammation, in that immune cells’ innate and adaptive responses usually favor tumor cell growth and progression. Sea cucumber extract Frondanol® A5 is known for its anti-inflammatory and immunostimulatory properties. In this study, Frondanol® A5 was tested for its chemopreventive activity against CRC using ApcMin+/+ mice. Frondanol® A5 had a significant inhibitory effect on small intestine and colon tumors. It increased innate immune responses against tumor formation; treated animals displayed an increase in phagocytosis and an increase in gamma-interferon-inducible lysosomal thiol reductase (GILT) expression. Frondanol® A5 markedly decreased inflammatory cytokines with decreased proliferation. Further, a significant decrease in the angiogenic marker VEGF was observed in treated tumors as illustrated by the cover micrograph (immunohistochemistry staining of VEGF in Frondanol®-A5-treated small intestinal polyps). These results suggest that Frondanol® A5 is a safer agent, which exhibits significant chemopreventive potential against intestinal tumorigenesis. For more information, see the article by Janakiram et al. (beginning on page 327).